This Cancer Test Could Become Routine—and a Big Seller, Says Analyst
In This Article:
Grail cutting-edge cancer blood test has stirred investor excitement many times in the past few years. With the stock down 55% from its February peak, Canaccord Genuity issued a Buy recommendation on Monday. Grail hopes its multicancer blood test will eventually become part of routine checkups.
Terms and Privacy Policy